array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Novartis Gene Therapies, Inc."
["slug"]=>
string(19) "a26d9-us-avexis-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c"
["description"]=>
string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP"
["address_street"]=>
string(24) "2275 Half Day Rd Ste 200"
["address_place"]=>
string(11) "Bannockburn"
["address_region"]=>
string(8) "Illinois"
["founding_date"]=>
string(10) "2010-02-28"
["website_domain"]=>
string(12) "novartis.com"
["website_url"]=>
string(24) "https://www.novartis.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(219)
["article_count"]=>
int(7826)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(60) "Novartis launches strategic review of listed entity in India"
["snippet_en"]=>
string(85) "Pharma giant Novartis has announced a strategic review of its listed entity in India."
["url"]=>
string(100) "https://www.thepharmaletter.com/article/novartis-launches-strategic-review-of-listed-entity-in-india"
["image_url"]=>
NULL
["source"]=>
string(19) "thepharmaletter.com"
["publication_date"]=>
string(10) "2024-02-19"
["categories"]=>
array(4) {
[0]=>
string(41) "E-commerce and Technological Developments"
[1]=>
string(10) "New Market"
[2]=>
string(14) "Product Review"
[3]=>
string(14) "Product Launch"
}
}
[1]=>
array(7) {
["title_en"]=>
string(85) "Novartis shares stronger: Novartis launches “strategic review” for Novartis India"
["snippet_en"]=>
string(93) "The pharmaceutical company Novartis has started a “strategic review” of a stake in India."
["url"]=>
string(132) "https://www.finanzen.ch/nachrichten/aktien/novartis-aktie-novartis-startet-strategische-ueberpruefung-fuer-novartis-india-1033078977"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/279c6ed1-a156-4cc2-9435-c7a01f55941d"
["source"]=>
string(11) "finanzen.ch"
["publication_date"]=>
string(10) "2024-02-19"
["categories"]=>
array(5) {
[0]=>
string(14) "Product Review"
[1]=>
string(10) "New Market"
[2]=>
string(14) "Product Launch"
[3]=>
string(12) "Stock Market"
[4]=>
string(10) "Divestment"
}
}
[2]=>
array(7) {
["title_en"]=>
string(51) "Novartis adj net income grows 6%, below market view"
["snippet_en"]=>
string(255) "By Ludwig Burger FRANKFURT (Reuters) -Novartis on Wednesday reported a gain of 6% in fourth-quarter adjusted net income, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, the Swi..."
["url"]=>
string(78) "https://whbl.com/2024/01/31/novartis-adj-net-income-grows-6-below-market-view/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/edab7310-5f16-47cb-8906-c5704ab40505"
["source"]=>
string(8) "whbl.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(4) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(15) "Market Movement"
[2]=>
string(14) "Product Launch"
[3]=>
string(31) "Financial Update/Profit Warning"
}
}
[3]=>
array(7) {
["title_en"]=>
string(57) "Insilico CEO Alex Zhavoronkov Discusses AI Drug Discovery"
["snippet_en"]=>
string(191) "The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology."
["url"]=>
string(101) "https://www.biospace.com/article/insilico-medicine-ceo-alex-zhavoronkov-discusses-ai-drug-discovery-/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/82dd044b-9c8d-487c-9e6a-64b9a430afeb"
["source"]=>
string(12) "biospace.com"
["publication_date"]=>
string(10) "2024-01-17"
["categories"]=>
array(3) {
[0]=>
string(5) "R & D"
[1]=>
string(15) "Deals & Tenders"
[2]=>
string(14) "Product Launch"
}
}
[4]=>
array(7) {
["title_en"]=>
string(89) "HCMC University Medicines Centre to manage transplantation by UMC Care mobile application"
["snippet_en"]=>
string(148) "Novartis Vietnam has partnered with the HCM City University Medicines Centre (UMC) to launch a Comprehensive Transplantation Management programme..."
["url"]=>
string(133) "http://bizhub.vn/corporate-news/hcmc-university-medicines-centre-to-manage-transplantation-by-umc-care-mobile-application_350736.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/e902af10-d36a-4379-8496-389e9dd1c5cf"
["source"]=>
string(9) "bizhub.vn"
["publication_date"]=>
string(10) "2023-12-05"
["categories"]=>
array(2) {
[0]=>
string(17) "Academic Research"
[1]=>
string(14) "Product Launch"
}
}
[5]=>
array(7) {
["title_en"]=>
string(51) "New drug to rescue leishmaniasis patients in Africa"
["snippet_en"]=>
string(96) "Leishmaniasis patients in Eastern Africa may soon benefit from a new drug set to be developed by"
["url"]=>
string(90) "https://newbusinessethiopia.com/health/new-drug-to-rescue-leishmaniasis-patients-in-africa"
["image_url"]=>
NULL
["source"]=>
string(23) "newbusinessethiopia.com"
["publication_date"]=>
string(10) "2023-11-27"
["categories"]=>
array(4) {
[0]=>
string(5) "R & D"
[1]=>
string(13) "Collaboration"
[2]=>
string(24) "Access and affordability"
[3]=>
string(14) "Product Launch"
}
}
[6]=>
array(7) {
["title_en"]=>
string(71) "Pharma Online - Richter introduces three products to the Russian market"
["snippet_en"]=>
string(120) "Richter is expanding its range in Russia with medicines suitable for the treatment of diabetes, Világgazdaság reports."
["url"]=>
string(95) "https://pharmaonline.hu/cikk/gyogyszeripar/harom-keszitmenyt-vezet-be-az-orosz-piacra-a-richter"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/25aae70a-85db-4ecc-8421-39ccccf7a1d6"
["source"]=>
string(15) "pharmaonline.hu"
["publication_date"]=>
string(10) "2023-11-03"
["categories"]=>
array(4) {
[0]=>
string(3) "War"
[1]=>
string(11) "Geopolitics"
[2]=>
string(18) "Expansion & Growth"
[3]=>
string(14) "Product Launch"
}
}
[7]=>
array(7) {
["title_en"]=>
string(101) "Emirates Oncology Society, Novartis Launch New Partnership to Transform Breast Cancer Care in the UAE"
["snippet_en"]=>
string(206) "Emirates Oncology Society, Novartis Launch New Partnership to Transform Breast Cancer Care in the UAE ‘United for Breast Cancer – A Commitment for Excellence and Innovation’ aims to address critica..."
["url"]=>
string(135) "https://uaenews247.com/2023/10/30/emirates-oncology-society-novartis-launch-new-partnership-to-transform-breast-cancer-care-in-the-uae/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/66908223-eb1c-4186-aa06-66fa2b0b47ac"
["source"]=>
string(14) "uaenews247.com"
["publication_date"]=>
string(10) "2023-10-30"
["categories"]=>
array(3) {
[0]=>
string(13) "Collaboration"
[1]=>
string(24) "Access and affordability"
[2]=>
string(14) "Product Launch"
}
}
[8]=>
array(7) {
["title_en"]=>
string(78) "Novartis launches its cholesterol injection in Spain with best-seller forecast"
["snippet_en"]=>
string(49) "Leqvio can exceed 2,000 million in global revenue"
["url"]=>
string(142) "https://cincodias.elpais.com/companias/2023-10-24/novartis-lanza-en-espana-su-inyeccion-contra-el-colesterol-con-prevision-de-superventas.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/aa3bcb69-a49d-45ab-9985-1d7800d0a4c9"
["source"]=>
string(10) "elpais.com"
["publication_date"]=>
string(10) "2023-10-24"
["categories"]=>
array(4) {
[0]=>
string(41) "E-commerce and Technological Developments"
[1]=>
string(10) "New Market"
[2]=>
string(14) "Product Launch"
[3]=>
string(31) "Financial Update/Profit Warning"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(527)
}
[1]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(450)
}
[2]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(433)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(306)
}
[4]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(302)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(242)
}
[6]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(238)
}
[7]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(232)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(194)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(189)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(179)
}
[11]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(163)
}
[12]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(161)
}
[13]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(160)
}
[14]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(143)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(133)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(130)
}
[17]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(125)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(119)
}
[19]=>
array(2) {
["name"]=>
string(8) "spin-off"
["count"]=>
int(114)
}
[20]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(112)
}
[21]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(108)
}
[22]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(98)
}
[23]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(98)
}
[24]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(85)
}
[25]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(85)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(81)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(80)
}
[28]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(78)
}
[29]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(74)
}
}
}
a26d9-us-avexis-inc
Novartis Gene Therapies, Inc.
Location
Illinois
Founded
2010-02-28
Website
https://www.novartis.com
Articles
7826 Articles
Category
Pharmaceutical Preparations
Description
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP
By Ludwig Burger FRANKFURT (Reuters) -Novartis on Wednesday reported a gain of 6% in fourth-quarter adjusted net income, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, the Swi...
The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.
Emirates Oncology Society, Novartis Launch New Partnership to Transform Breast Cancer Care in the UAE ‘United for Breast Cancer – A Commitment for Excellence and Innovation’ aims to address critica...
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
